Intracellular Bacteria and Protozoa - Intracellular Delivery: Fundamentals and Applications - page 809

Smith I (2003) Mycobacterium tuberculosis pathogenesis and molecular determinants of viru-
lence. Clin Microbiol Rev 16: 463-496
Smith JE, Pirson P, Sinden RE (1983) Studies on the kinetics of uptake and distribution of free
and liposome-entrapped primaquine, and of sporozoites by isolated perfused rat liver. Ann
Trop Med Parasitol 77: 379-386
Solomon M, Baum S, Barzilai A, Scope A, Trau H, Schwartz E (2007) Liposomal amphotericin
B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania brazil-
iensis . J Am Acad Dermatol 56: 612-616
Sosa Estani S, Segura EL (1999) Treatment of Trypanosoma cruzi infection in the undetermined
phase. Experience and current guidelines in Argentina. Mem Inst Oswaldo Cruz 94: 363-365
Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C (1998) Efficacy of
chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease. Am
J Trop Med Hyg 59: 526-529
Sosnik A, Carcaboso ÁM, Glisoni RJ, Moretton MA, Chiappetta DA (2010) New old challenges
in tuberculosis: Potentially effective nanotechnologies in drug delivery. Adv Drug Del Rev 62:
547-559
Stern ST, Hall JB, Yu LL, Wood LJ, Paciotti GF, Tamarkin L, Long SE, McNeil SE (2010)
Translational considerations for cancer nanomedicine. J Control Release 146: 164-174
Strosberg AM, Barrio K, Stinger VH, Tashker J, Wilbur JC, Wilson L, Woo K (2007) Chagas
disease: a Latin American nemesis. Report Institute for OneWorld Health
Suárez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ (2001)
Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis:
screening in an infectious disease model. Pharm Res 18 (9): 1315-1319
Swenson CE, Stewart KA, Hammett JL, Fitzsimmons WE, Ginsberg RS (1990) Pharmacokinetics
and in vivo activity of liposome-encapsulated gentamicin. Antimicrob Agents Chemother 34:
235-240
Tan ML, Choong PFM, Dass CR (2010) Recent developments in liposomes, microparticles and
nanoparticles for protein and peptide drug delivery. Peptides 31: 184-193
The Union (2008) Tuberculosis. The International Union Against Tuberculosis and Lung Disease.
http://www.theunion.org/tuberculosis/tuberculosis.html . Accessed February 2008
Threlfall EJ, de Pinna E, Day M, Lawrence J, Jones J (2008) Alternatives to ciprofloxacin use for
enteric Fever, United kingdom. Emerg Infect Dis 14: 860-861
Tian Y, Bromberg L, Lin SN, Hatton TA, Tam KC (2007) Complexation and release of doxorubi-
cin from its complexes with pluronic P85-b-poly(acrylic acid) block copolymers. J Control
Release 121:137-145
Toit LC, Pillay V, Danckwerts MP (2006) Tuberculosis chemotherapy: current drug delivery
approaches. Resp Res 7: 1-18
Torchilin V (2009) Intracellular delivery of protein and peptide therapeutics. Drug Discov Today
Technol 5: e95-e103
Tulkens PM (1991) Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol
Infect Dis 10: 100-106
van den Broek PJ (1989) Antimicrobial drugs, microorganisms and phagocytes. Rev Infect Dis 11:
213-245
Vardy D, Barenholz Y, Naftoliev N, Klaus S, Gilead L, Frankenburg S (2001) Efficacious topical
treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B. Trans R Soc
Trop Med Hyg 95(2): 184-186
Verma AK, Sachin K, Saxena A, Bohidar HB (2005) Release kinetics from bio-polymeric nano-
particles encapsulating protein synthesis inhibitor-cycloheximide, for possible therapeutic
applications. Curr Pharm Biotechnol 6: 121-130
Vyas SP, Kannan ME, Jain S, Mishra V, Singh P (2004) Design of liposomal aerosols for
improved delivery of rifampicin to alveolar macrophages. Int J Pharm 269: 37-49
Webb MS, Boman NL, Wiseman DJ, Saxon D, Sutton K, Wong KF, Logan P, Hope MJ (1998)
Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and